Arca
Skip to content
Tools
Tools

IL2RA: Interleukin-2 receptor subunit alpha

Receptor for interleukin-2.

  • Drugs that act on it: 4
  • Approved: 0
  • In phases 1 to 3: 4
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on IL2RA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1
  • Other 2

Approved0

    Phase 31

    • Inolimomab

    Phase 22

    • Camidanlumab tesirine
    • LMB-2

    Phase 11

    • Anti-tac 90 y-hat

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • ElsaLys Biotech125%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Interleukin-2 receptor alpha chain binding agent; the rest name their own mechanism.
    InolimomabPhase 3ElsaLys BiotechAntibodyAntagonistInterleukin-2 receptor alpha chain antagonist0
    Camidanlumab tesirinePhase 2ADC TherapeuticsAntibody-drug conjugateBinding agent0
    LMB-2Phase 2—OtherBinding agent0
    Anti-tac 90 y-hatPhase 1—OtherBinding agent0

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Immunodeficiency due to CD25 deficiency0.79
    • Type 1 diabetes mellitus0.63
    • Primary cutaneous T-cell non-Hodgkin lymphoma0.56
    • Hypothyroidism0.55
    • Kidney transplant0.53
    • Atopic eczema0.52
    • Crohn disease0.52

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1778, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01589, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.